newsfilter
← Latest News
GlobeNewswire·

Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026

  • Veru Inc. will present post hoc analysis results from the Phase 2b QUALITY study at ObesityWeek 2026, focusing on physical function in patients aged 65+ receiving GLP-1 RA therapy.
  • Dr. Gary Barnette, Chief Scientific Officer, will deliver a podium presentation titled "Enobosarm in Patients with Obesity on Semaglutide: Quality Weight Loss & Better Physical Function" on November 16, 2026, at 5:15 PM ET.
  • The Phase 2b PLATEAU clinical trial evaluating enobosarm 3mg combined with semaglutide in patients aged 65+ with obesity has exceeded its enrollment target, reaching 239 patients versus the 200-patient goal.
  • The PLATEAU study aims to assess enobosarm's ability to preserve lean mass & physical function to achieve incremental weight reduction over 68 weeks, with interim DXA data expected in Q1 2027 & final topline data in Q4 2027.
  • Previous Phase 2b QUALITY study results demonstrated that enobosarm plus semaglutide preserved lean mass & physical function while increasing fat loss, & enobosarm monotherapy prevented weight regain after semaglutide discontinuation.
  • Veru plans to pursue a Phase 2b clinical study for sabizabulin in metastatic pancreatic cancer patients resistant to daraxonrasib, seeking FDA regulatory clarity via a pre-IND meeting in Q4 2026.
  • Sabizabulin is an oral microtubule targeting agent designed to overcome resistance to KRAS inhibitors & chemotherapy by disrupting microtubule polymerization & downregulating βIII-tubulin isoforms.
  • Pancreatic cancer remains a highly lethal disease with a median overall survival of 4 months, & over 90% of cases involve KRAS mutations driving tumor progression & chemoresistance.
  • Forward-looking statements warn of risks including potential clinical trial failures, funding limitations, regulatory delays, & the possibility of Novo Nordisk terminating the clinical supply agreement for semaglutide.
Company
Veru Inc.
Keywords
Nasdaq:VERU, Veru Inc.